Suppr超能文献

有机溶剂对人血清白蛋白纳米颗粒理化性质的影响

The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles.

作者信息

Mohammad-Beigi Hossein, Shojaosadati Seyed Abbas, Morshedi Dina, Mirzazadeh Negar, Arpanaei Ayyoob

机构信息

Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran.

Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

出版信息

Iran J Biotechnol. 2016 Mar;14(1):45-50. doi: 10.15171/ijb.1168.

Abstract

BACKGROUND

Recently, applications of albumin nanoparticles as drug delivery carriers have increased. Most toxicology studies have shown that surface chemistry and size of nanoparticles play an important role in biocompatibility and toxicity.

OBJECTIVE

The effect of desolvating agents with different chemical properties on the size of synthesized HSA NPs was investigated.

MATERIALS AND METHODS

Acetone, ethanol, methanol, and acetonitrile were used to synthesize HSA NPs with controllable size by desolvation method. Scanning electron microscopy (SEM), dynamic light scattering (DLS), and circular dichroism (CD) were employed to characterize produced particles. Finally, the toxicity of HSA NPs synthesized under different conditions was evaluated on PC-12 cells.

RESULTS

The sizes of synthesized particles differed according to the different solvents used. The sizes were 275.3 nm, 155.3 nm, 100.11 nm, and 66.2 nm for acetonitrile, ethanol, acetone, and methanol, respectively. CD showed that larger NPs had more changes in the secondary structures. Finally, the toxicity monitored on the cultured PC-12 cells showed no significant toxic effect through treating with these NPs at different concentrations (0-500 μg.mL).

CONCLUSIONS

The size of HSA NPs has a strong dependency on the desolvating agent. The mechanism in which the desolvating agent affects the size of HSA NPs is complex. Various factors such as dielectric constant, polarity, functional groups, and hydrogen bonding of the solvents have the potential to affect the size and structure of HSA NPs. CD analysis suggested that the solvent denaturing capability had a critical effect on the HSA particle size. The stronger denaturing capability of the solvent resulted in the larger HSA particle size.

摘要

背景

近年来,白蛋白纳米颗粒作为药物递送载体的应用有所增加。大多数毒理学研究表明,纳米颗粒的表面化学性质和尺寸在生物相容性和毒性方面起着重要作用。

目的

研究具有不同化学性质的去溶剂化剂对合成的人血清白蛋白纳米颗粒(HSA NPs)尺寸的影响。

材料与方法

使用丙酮、乙醇、甲醇和乙腈通过去溶剂化法合成尺寸可控的HSA NPs。采用扫描电子显微镜(SEM)、动态光散射(DLS)和圆二色性(CD)对制备的颗粒进行表征。最后,评估在不同条件下合成的HSA NPs对PC-12细胞的毒性。

结果

根据所使用的不同溶剂,合成颗粒的尺寸有所不同。乙腈、乙醇、丙酮和甲醇合成的颗粒尺寸分别为275.3 nm、155.3 nm、100.11 nm和66.2 nm。CD显示较大的纳米颗粒二级结构变化更大。最后,对培养的PC-12细胞进行毒性监测,结果表明在不同浓度(0 - 500 μg/mL)下用这些纳米颗粒处理未显示出明显的毒性作用。

结论

HSA NPs的尺寸强烈依赖于去溶剂化剂。去溶剂化剂影响HSA NPs尺寸的机制很复杂。溶剂的介电常数、极性、官能团和氢键等各种因素都有可能影响HSA NPs的尺寸和结构。CD分析表明溶剂的变性能力对HSA颗粒尺寸有关键影响。溶剂的变性能力越强,HSA颗粒尺寸越大。

相似文献

3
Albumin nanoparticles with predictable size by desolvation procedure.
J Microencapsul. 2012;29(2):138-46. doi: 10.3109/02652048.2011.635218.
5
Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
Int J Pharm. 2011 Jan 17;403(1-2):285-91. doi: 10.1016/j.ijpharm.2010.10.041. Epub 2010 Oct 28.
6
Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Curr Drug Deliv. 2014;11(3):359-70. doi: 10.2174/15672018113109990050.
7
Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies.
Pharmaceutics. 2019 Aug 12;11(8):410. doi: 10.3390/pharmaceutics11080410.
9
Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
Int J Pharm. 2003 May 12;257(1-2):169-80. doi: 10.1016/s0378-5173(03)00134-0.
10
Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation.
Biomed Eng Online. 2019 Jan 31;18(1):11. doi: 10.1186/s12938-019-0624-7.

引用本文的文献

1
Green Solvent-Based Extraction of Lipids and Proteins from : A Sustainable Approach and Cytotoxic Activity.
Food Sci Anim Resour. 2025 May;45(3):807-820. doi: 10.5851/kosfa.2024.e62. Epub 2025 May 1.
2
Clarithromycin-Loaded Albumin-Based Nanoparticles for Improved Antibacterial and Anticancer Performance.
Pharmaceutics. 2025 May 31;17(6):729. doi: 10.3390/pharmaceutics17060729.
3
Microfluidics-Assisted Formulation of Polymeric Oxytocin Nanoparticles for Targeted Brain Delivery.
Pharmaceutics. 2025 Apr 1;17(4):452. doi: 10.3390/pharmaceutics17040452.
4
Periodate-Mediated Cross-Linking for the Preparation of Catechol Conjugated Albumin Nanoparticles Used for in Vitro Drug Delivery.
ACS Appl Bio Mater. 2025 Mar 17;8(3):2182-2193. doi: 10.1021/acsabm.4c01737. Epub 2025 Feb 14.
6
Reproducible Synthesis of Biocompatible Albumin Nanoparticles Designed for Intra-articular Administration of Celecoxib to Treat Osteoarthritis.
ACS Appl Mater Interfaces. 2024 Mar 27;16(12):14633-14644. doi: 10.1021/acsami.4c02243. Epub 2024 Mar 14.
7
Unraveling the Formation of Gelatin Nanospheres by Means of Desolvation.
Nano Lett. 2023 Dec 13;23(23):11091-11098. doi: 10.1021/acs.nanolett.3c03459. Epub 2023 Nov 15.
8
10

本文引用的文献

1
In vitro toxicity of different-sized ZnO nanoparticles in Caco-2 cells.
Nanoscale Res Lett. 2013 Nov 21;8(1):496. doi: 10.1186/1556-276X-8-496.
2
Influence of gold nanoparticles on the kinetics of α-synuclein aggregation.
Nano Lett. 2013;13(12):6156-63. doi: 10.1021/nl403490e. Epub 2013 Nov 18.
5
Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
Int J Pharm. 2013 Apr 15;447(1-2):62-9. doi: 10.1016/j.ijpharm.2013.02.043. Epub 2013 Feb 27.
6
Albumin nanoparticles with predictable size by desolvation procedure.
J Microencapsul. 2012;29(2):138-46. doi: 10.3109/02652048.2011.635218.
7
Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine.
Eur J Pharm Sci. 2011 Nov 20;44(4):559-65. doi: 10.1016/j.ejps.2011.10.002. Epub 2011 Oct 8.
8
Albumin-based nanoparticles as potential controlled release drug delivery systems.
J Control Release. 2012 Jan 30;157(2):168-82. doi: 10.1016/j.jconrel.2011.07.031. Epub 2011 Aug 1.
9
Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology.
AAPS PharmSciTech. 2010 Sep;11(3):1206-11. doi: 10.1208/s12249-010-9487-8. Epub 2010 Aug 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验